Menu
Log in
Forgot password
Log in
Forgot password

News

  • Home
  • Resources
  • Literature Updates
  • FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

16 Jun 2022 12:15 PM | Anonymous

Ralf-Dieter Hofheinz, MD1; Kirsten Merx, MD1; Georg M. Haag, MD2; Christoph Springfeld, MD2; Thomas Ettrich, MD3; Kersten Borchert, MD4; Albrecht Kretzschmar, MD5; Christian Teschendorf, MD6; Gabriele Siegler, MD7; Matthias P. Ebert, MD1,8,9; Eray Goekkurt, MD10; Rolf Mahlberg, MD11; Nils Homann, MD12; Daniel Pink, MD13,14; Wolf Bechstein, MD15; Peter Reichardt, MD16; Hagen Flach17; Timo Gaiser, MD18; Achim Battmann, MD19; Fuat S. Oduncu, MD20; Maria Loose, PhD21; Disorn Sookthai, MSc21; Claudia Pauligk, PhD21; Thorsten O. Göetze, MD21,22; and Salah-Eddin Al-Batran, MD21,22

Read Abstract: FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group

Affiliated Societies



International  Interdisciplinary  Everything Esophageal


The International Society for Diseases of the Esophagus is a 501(c)3 non-profit organization. © International Society for Disease of the Esophagus – ISDE 2024 | Any unauthorized use or reproduction of the content is prohibited without explicit permission.

General Inquiries: info@isde.net
Membership Questions: membership@isde.net

Powered by Wild Apricot Membership Software